Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$3.15 -0.01 (-0.32%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.16 +0.01 (+0.32%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$3.15
$3.30
50-Day Range
$1.47
$3.60
52-Week Range
$1.47
$17.31
Volume
35,232 shs
Average Volume
67,823 shs
Market Capitalization
$76.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ARTV MarketRank™: 

Artiva Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 385th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artiva Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Artiva Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.95) to ($2.83) per share.

  • Price to Book Value per Share Ratio

    Artiva Biotherapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Artiva Biotherapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ARTV.
  • Dividend Yield

    Artiva Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Artiva Biotherapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ARTV.
  • News Sentiment

    Artiva Biotherapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Artiva Biotherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artiva Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,615.00 in company stock.

  • Percentage Held by Insiders

    21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Artiva Biotherapeutics' insider trading history.
Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARTV Stock News Headlines

Artiva Biotherapeutics Reports Progress in Clinical Trials
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Artiva (ARTV) Q2 Loss Widens 19.7%
Artiva Biotherapeutics Rings the Closing Bell
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $10.08 on January 1st, 2025. Since then, ARTV shares have decreased by 68.8% and is now trading at $3.15.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.03.

Artiva Biotherapeutics (ARTV) raised $167 million in an IPO on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share.

Top institutional shareholders of Artiva Biotherapeutics include Geode Capital Management LLC (0.65%), Marshall Wace LLP (0.21%), Jane Street Group LLC (0.18%) and Qube Research & Technologies Ltd (0.16%). Insiders that own company stock include Yong-Jun Huh, Global Strategic Fund I Venbio and Fred Aslan.
View institutional ownership trends
.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
8/06/2025
Today
8/30/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
CIK
1817241
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$12.00
Potential Upside/Downside
+439.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.37 million
Net Margins
N/A
Pretax Margin
-26,045.02%
Return on Equity
-42.60%
Return on Assets
-37.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.84
Quick Ratio
13.84

Sales & Book Value

Annual Sales
$250 thousand
Price / Sales
307.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.10 per share
Price / Book
0.52

Miscellaneous

Outstanding Shares
24,430,000
Free Float
19,199,000
Market Cap
$76.95 million
Optionable
N/A
Beta
N/A

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners